OCTON HEALTH 360
Holistic clinical AI
 All cancers
Use with patients
Cancer module

Liver Cancer (HCC)

LI-RADS-aligned surveillance in chronic liver disease (HBV, HCV, MASLD, cirrhosis).

Reporting system
LI-RADS (LR-1 to LR-5/M)
Imaging modalities
  • Abdominal Ultrasound
  • Multiphasic CT
  • MRI (Gd-EOB)
  • Pathology
Key findings OCTON surfaces
  • Arterial phase hyperenhancement
  • Portal venous / delayed washout
  • Enhancing capsule
  • Threshold growth ≥ 50% in ≤ 6 mo
  • Tumor in vein
Evidence base
  • AASLD Practice Guidance 2023 — HCC surveillance every 6 mo
  • EASL Clinical Practice Guidelines 2023
  • BMJ 2024;385:e078866 — MASLD/MASH and HCC risk
Risk questionnaire
  • · What is your age?
  • · Chronic hepatitis B infection?
  • · Chronic hepatitis C infection?
  • · Diagnosed cirrhosis of any cause?
  • · Heavy alcohol use (> 3 drinks/day for > 10 years)?
  • · Diagnosed MASLD / MASH or type 2 diabetes with obesity?
  • · Significant aflatoxin exposure (endemic region)?
  • · First-degree relative with HCC?
See OCTON in action · early-detection demos
03 / 24
Liver cancerYou're herehigh · 71/100MRI · LI-RADS 5
1.8 cm LI-RADS 5 nodule on cirrhosis surveillance MRI
1.8 cm hepatic nodule with arterial-phase hyperenhancement and washout — LI-RADS 5 (definite HCC).
View demo
Ready to use this module?
Open OCTON and analyze a scan.
Start